You are here: Industry Insights > monoclonal antibody

News List

Tychan Completes Human Safety Studies for Monoclonal Antibody against Zika americanpharmaceuticalreview
October 30, 2018
Tychan has successfully completed Phase-1 safety trials for Tyzivumab, its first-in-class monoclonal antibody (mAb) therapeutic for Zika, in Singapore.
Jobs and Elon Musk in the Life Sciences Community? Stephen Hoge will Disrupt the Entire Monoclonal Antibody Industry with mRNA Therapy Chen Bin
September 21, 2018
Stephen Hoge will Disrupt the Entire Monoclonal Antibody Industry with mRNA Therapy
Atreca bags $125M as solid tumor trial comes into view fiercebiotech
September 13, 2018
Atreca’s cranking of its discovery engine has uncovered more than 1,000 antibodies.
Y-mAbs preps $92M IPO to push lead assets through regulatory filing fiercebiotech
August 28, 2018
Naxitamab and omburtamab are in pivotal phase 2 studies for relapsed/refractory high-risk neuroblastoma and central nervous system/leptomeningeal metastases from neuroblastoma, respectively. (Y-mAbs Therapeutics)
I-Mab Biopharma, MorphoSys declares China IND Submission of monoclonal antibody biospectrumasia
August 10, 2018
The company has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.
Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(5) Siyi
June 11, 2018
TNFα inhibitors have made brilliant achievements since the launch of the first relevant monoclonal antibody...
Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(3) Siyi
June 08, 2018
Among other autoimmune diseases, anti-IL-12/23 Stelara does not have advantages over TNFα inhibitors...
The Most Comprehensive Summary Ever! About the Chinese-produced Anti-PD-1/PD-L1 Drugs Caicai
April 13, 2018
The anti-PD-1 monoclonal antibody JS001 of Junshi has been completed the first patient administration of Phase I clinical trial in the U.S. several days ago, which has aroused wide attention from the insiders.
The Future Pattern of Biosimilars in China zhulikou431
March 02, 2018
The biosimilars in China have entered the fast lane of development, and CFDA is now open to and encouraging biosimilar R&D...
Opdivo May Be the First Marketed in China, Chinese Pharmaceutical Enterprises are Catching up Fast! Zhixing
January 17, 2018
Anti-PD-1 monoclonal antibodies are very popular with pharmaceutical enterprises, however, it is hard to find such monoclonal antibody in China.

Previous page 1 2 3 4 5 6 Next page